The Use of Hepatitis C Virus–Positive Organs in Hepatitis C Virus–Negative Recipients


    • Kwong A.J.
    • Kim W.R.
    • Lake J.R.
    • et al.

    OPTN/SRTR 2019 annual data report: liver.

    Am J Transplant. 2021; 21: 208-315

    • Reese P.P.
    • Abt P.L.
    • Blumberg E.A.
    • et al.

    Transplanting hepatitis C–positive kidneys.

    N Engl J Med. 2015; 373: 303-305

    • Homkrailas P.
    • Bunnapradist S.

    Association between ethnicity and kidney transplant waitlist outcomes beyond estimated post-transplant survival score.

    Transpl Int. 2021; 34: 1837-1844https://doi.org/10.1111/tri.13965

    • Aslam S.
    • Grossi P.
    • Schlendorf K.H.
    • et al.

    Utilization of hepatitis C virus-infected organ donors in cardiothoracic transplantation: an ISHLT expert consensus statement.

    J Heart Lung Transplant. 2020; 39: 418-432

    • Weinfurtner K.
    • Reddy K.R.

    Hepatitis C viraemic organs in solid organ transplantation.

    J Hepatol. 2021; 74: 716-733

    • Cotter T.G.
    • Paul S.
    • Sandıkçı B.
    • et al.

    Increasing utilization and excellent initial outcomes following liver transplant of hepatitis C virus (HCV)-viremic donors into HCV-negative recipients: outcomes following liver transplant of HCV-viremic donors.

    Hepatology. 2019; 69: 2381-2395https://doi.org/10.1002/hep.30540

  • Victory and defeat at Heraclea – treating hepatitis C infection following liver transplantation with telaprevir and boceprevir.

    J Hepatol. 2014; 60: 6-8

    • Coilly A.
    • Roche B.
    • Dumortier J.
    • et al.

    Safety and efficacy of protease inhibitors to treat hepatitis C after liver transplantation: a multicenter experience.

    J Hepatol. 2014; 60: 78-86

    • Bowring M.G.
    • Kucirka L.M.
    • Massie A.B.
    • et al.

    Changes in utilization and discard of hepatitis C-infected donor livers in the recent era.

    Am J Transpl. 2017; 17: 519-527

    • Fabrizi F.
    • Martin P.
    • Dixit V.
    • et al.

    Meta-analysis of observational studies: hepatitis C and survival after renal transplant.

    J Viral Hepat. 2014; 21: 314-324

    • Durand C.M.
    • Bowring M.G.
    • Thomas A.G.
    • et al.

    The drug overdose epidemic and deceased-donor transplantation in the United States: a national registry study.

    Ann Intern Med. 2018; 168: 702-711

    • Kwong A.J.
    • Wall A.
    • Melcher M.
    • et al.

    Liver transplantation for hepatitis C virus (HCV) non-viremic recipients with HCV viremic donors.

    Am J Transpl. 2019; 19: 1380-1387

    • Gonzalez S.A.
    • Trotter J.F.

    The rise of the opioid epidemic and hepatitis C–positive organs: a new era in liver transplantation.

    Hepatology. 2018; 67: 1600-1608https://doi.org/10.1002/hep.29572

    • Cotter T.G.
    • Aronsohn A.
    • Reddy K.G.
    • et al.

    Liver transplantation of HCV-viremic donors into HCV-negative recipients in the United States: increasing frequency with profound geographic variation.

    Transplantation. 2021; 105: 1285-1290

    • Da B.L.
    • Ezaz G.
    • Kushner T.
    • et al.

    Donor characteristics and regional differences in the utilization of HCV-positive donors in liver transplantation.

    JAMA Netw Open. 2020; 3: e2027551

  • Graft and patient survival after adult live donor liver transplantation compared to a matched cohort who received a deceased donor transplantation.

    Liver Transplant. 2004; 10: 1263-1268

    • Jandovitz N.
    • Nair V.
    • Grodstein E.
    • et al.

    Hepatitis C-positive donor to negative recipient kidney transplantation: a real-world experience.

    Transpl Infect Dis. 2021; 23: e13540

    • Ariyamuthu V.K.
    • Sandikci B.
    • AbdulRahim N.
    • et al.

    Trends in utilization of deceased donor kidneys based on hepatitis C virus status and impact of public health service labeling on discard.

    Transpl Infect Dis. 2020; 22: e13204

    • Nair S.P.
    • Marella H.K.
    • Maliakkal B.
    • et al.

    Transplantation of liver from hepatitis C-infected donors to hepatitis C RNA-negative recipients: histological and virologic outcome.

    Clin Transplant. 2021; 35: e14281

    • Whitcomb E.
    • Choi W.T.
    • Jerome K.R.
    • et al.

    Biopsy specimens from allograft liver contain histologic features of hepatitis C virus infection after virus eradication.

    Clin Gastroenterol Hepatol. 2017; 15: 1279-1285

    • Anwar N.
    • Kaiser T.E.
    • Bari K.
    • et al.

    Use of hepatitis C nucleic acid test–positive liver allografts in hepatitis C virus seronegative recipients.

    Liver Transplant. 2020; 26: 673-680

    • Barsoum R.S.
    • William E.A.
    • Khalil S.S.

    Hepatitis C and kidney disease: a narrative review.

    J Adv Res. 2017; 8: 113-130

  • Letter to the editor: safety first: favoring prophylactic/preemptive over delayed treatment in D+/R- transplants.

    Hepatology. 2020; 72: 787

    • Gupta E.
    • Bajpai M.
    • Choudhary A.

    Hepatitis C virus: screening, diagnosis, and interpretation of laboratory assays.

    Asian J Transfus Sci. 2014; 8: 19-25

    • Colin C.
    • Lanoir D.
    • Touzet S.
    • et al.

    Sensitivity and specificity of third-generation hepatitis C virus antibody detection assays: an analysis of the literature.

    J Viral Hepat. 2001; 8: 87-95

    • Castillo I.
    • Rodríguez-Iñigo E.
    • López-Alcorocho J.M.
    • et al.

    Hepatitis C virus replicates in the liver of patients who have a sustained response to antiviral treatment.

    Clin Infect Dis. 2006; 43: 1277-1283

    • Lin A.
    • Thadareddy A.
    • Goldstein M.J.
    • et al.

    Immune suppression leading to hepatitis C virus re-emergence after sustained virological response.

    J Med Virol. 2008; 80: 1720-1722

    • Vento S.
    • Cainelli F.
    • Longhi M.S.

    Reactivation of replication of hepatitis B and C viruses after immunosuppressive therapy: an unresolved issue.

    Lancet Oncol. 2002; 3: 333-340

    • Bari K.
    • Luckett K.
    • Kaiser T.
    • et al.

    Hepatitis C transmission from seropositive, nonviremic donors to non-hepatitis C liver transplant recipients.

    Hepatology. 2018; 67: 1673-1682

    • Luckett K.
    • Kaiser T.E.
    • Bari K.
    • et al.

    Use of hepatitis C virus antibody-positive donor livers in hepatitis C nonviremic liver transplant recipients.

    J Am Coll Surg. 2019; 228: 560-567

    • Bunchorntavakul C.
    • Reddy K.R.

    Treat chronic hepatitis C virus infection in decompensated cirrhosis – pre- or post-liver transplantation? the ironic conundrum in the era of effective and well-tolerated therapy.

    J Viral Hepat. 2016; 23: 408-418

    • Aqel B.
    • Wijarnpreecha K.
    • Pungpapong S.
    • et al.

    Outcomes following liver transplantation from HCV-seropositive donors to HCV-seronegative recipients.

    J Hepatol. 2021; 74: 873-880

    • Bethea E.D.
    • Gaj K.
    • Gustafson J.L.
    • et al.

    Pre-emptive pangenotypic direct acting antiviral therapy in donor HCV-positive to recipient HCV-negative heart transplantation: an open-label study.

    Lancet Gastroenterol Hepatol. 2019; 4: 771-780

    • Bohorquez H.
    • Bugeaud E.
    • Bzowej N.
    • et al.

    Liver transplantation using hepatitis C virus-viremic donors into hepatitis C virus-aviremic recipients as standard of care.

    Liver Transpl. 2021; 27: 548-557

    • Crismale J.F.
    • Khalid M.
    • Bhansali A.
    • et al.

    Liver, simultaneous liver-kidney, and kidney transplantation from hepatitis C-positive donors in hepatitis C-negative recipients: a single-center study.

    Clin Transplant. 2020; 34: e13761

    • Hudson M.R.
    • Webb A.R.
    • Logan A.T.
    • et al.

    Outcomes of hepatitis C virus nucleic acid testing positive donors in aviremic recipients with delayed direct-acting antiviral initiation.

    Clin Transplant. 2021; 35: e14386https://doi.org/10.1111/ctr.14386

    • Kapila N.
    • Menon K.V.N.
    • Al-Khalloufi K.
    • et al.

    Hepatitis C virus NAT-positive solid organ allografts transplanted into hepatitis C virus-negative recipients: a real-world experience.

    Hepatology. 2020; 72: 32-41

    • Said A.
    • Weiss M.
    • Varhelyi A.
    • et al.

    Utilization of hepatitis C viremic donors for liver transplant recipients without hepatitis C. A Veterans Transplant Center Report.

    Transpl Infect Dis. 2021; 23: e13466https://doi.org/10.1111/tid.13466

    • Sobotka L.A.
    • Mumtaz K.
    • Wellner M.R.
    • et al.

    Outcomes of hepatitis C virus seropositive donors to hepatitis C virus seronegative liver recipients: a large single center analysis.

    Ann Hepatol. 2021; 24: 100318

    • Terrault N.A.
    • Berenguer M.
    • Strasser S.I.
    • et al.

    International Liver Transplantation Society consensus statement on hepatitis C management in liver transplant recipients.

    Transplantation. 2017; 101: 956-967

    • Ting P.S.
    • Hamilton J.P.
    • Gurakar A.
    • et al.

    Hepatitis C-positive donor liver transplantation for hepatitis C seronegative recipients.

    Transpl Infect Dis. 2019; 21: e13194

    • Terrault N.A.
    • Burton J.
    • Ghobrial M.
    • et al.

    Prospective multicenter study of early antiviral therapy in liver and kidney transplant recipients of HCV-viremic donors.

    Hepatology. 2021; 73: 2110-2123

    • Houssel-Debry P.
    • Coilly A.
    • Fougerou-Leurent C.
    • et al.

    12 Weeks of a ribavirin-free sofosbuvir and nonstructural protein 5A inhibitor regimen is enough to treat recurrence of hepatitis C after liver transplantation.

    Hepatology. 2018; 68: 1277-1287

    • Kwok R.M.
    • Ahn J.
    • Schiano T.D.
    • et al.

    Sofosbuvir plus ledispasvir for recurrent hepatitis C in liver transplant recipients.

    Liver Transpl. 2016; 22: 1536-1543

    • Sise M.E.
    • Goldberg D.S.
    • Kort J.J.
    • et al.

    Multicenter study to transplant hepatitis C–infected kidneys (MYTHIC): an open-label study of combined glecaprevir and pibrentasvir to treat recipients of transplanted kidneys from deceased donors with hepatitis C virus infection.

    J Am Soc Nephrol. 2020; 31: 2678-2687

    • Durand C.M.
    • Barnaba B.
    • Yu S.
    • et al.

    Four-week direct-acting antiviral prophylaxis for kidney transplantation from hepatitis C-viremic donors to hepatitis C-negative recipients: an open-label nonrandomized study.

    Ann Intern Med. 2021; 174: 137-138

    • Reyentovich A.
    • Gidea C.G.
    • Smith D.
    • et al.

    Outcomes of the treatment with glecaprevir/pibrentasvir following heart transplantation utilizing hepatitis C viremic donors.

    Clin Transplant. 2020; 34: e13989

    • Smith D.E.
    • Chen S.
    • Fargnoli A.
    • et al.

    Impact of early initiation of direct-acting antiviral therapy in thoracic organ transplantation from hepatitis C virus positive donors.

    Semin Thorac Cardiovasc Surg. 2021; 33: 407-415

    • Woolley A.E.
    • Singh S.K.
    • Goldberg H.J.
    • et al.

    Heart and lung transplants from HCV-infected donors to uninfected recipients.

    N Engl J Med. 2019; 380: 1606-1617

    • Gupta G.
    • Yakubu I.
    • Bhati C.S.
    • et al.

    Ultra-short duration direct acting antiviral prophylaxis to prevent virus transmission from hepatitis C viremic donors to hepatitis C negative kidney transplant recipients.

    Am J Transplant. 2020; 20: 739-751

    • Murali A.R.
    • Chandra S.
    • Stewart Z.
    • et al.

    Graft versus host disease after liver transplantation in adults: a case series, review of literature, and an approach to management.

    Transplantation. 2016; 100: 2661-2670

    • Chan E.Y.
    • Larson A.M.
    • Gernsheimer T.B.
    • et al.

    Recipient and donor factors influence the incidence of graft-vs.-host disease in liver transplant patients.

    Liver Transpl. 2007; 13: 516-522

    • Narang T.K.
    • Ahrens W.
    • Russo M.W.

    Post–liver transplant cholestatic hepatitis C: a systematic review of clinical and pathological findings and application of consensus criteria.

    Liver Transplant. 2010; 16: 1228-1235https://doi.org/10.1002/lt.22175

    • Verna E.C.
    • Abdelmessih R.
    • Salomao M.A.
    • et al.

    Cholestatic hepatitis C following liver transplantation: an outcome-based histological definition, clinical predictors, and prognosis.

    Liver Transpl. 2013; 19: 78-88

    • Doughty A.L.
    • Spencer J.D.
    • Cossart Y.E.
    • et al.

    Cholestatic hepatitis after liver transplantation is associated with persistently high serum hepatitis C virus RNA levels.

    Liver Transpl Surg. 1998; 4: 15-21

  • The natural history and outcome of liver transplantation in hepatitis C virus-infected recipients.

    Liver Transplant. 2003; 9: S28-S34

    • Satapathy S.K.
    • Sclair S.
    • Fiel M.I.
    • et al.

    Clinical characterization of patients developing histologically-proven fibrosing cholestatic hepatitis C post-liver transplantation.

    Hepatol Res. 2011; 41: 328-339

    • Schluger L.K.
    • Sheiner P.A.
    • Thung S.N.
    • et al.

    Severe recurrent cholestatic hepatitis C following orthotopic liver transplantation.

    Hepatology. 1996; 23: 971-976

    • Shuhart M.C.
    • Bronner M.P.
    • Gretch D.R.
    • et al.

    Histological and clinical outcome after liver transplantation for hepatitis C.

    Hepatology. 1997; 26: 1646-1652

    • Molnar M.Z.
    • Nair S.
    • Cseprekal O.
    • et al.

    Transplantation of kidneys from hepatitis C-infected donors to hepatitis C-negative recipients: single center experience.

    Am J Transpl. 2019; 19: 3046-3057

    • Levitsky J.
    • Goldberg D.
    • Smith A.R.
    • et al.

    Acute rejection increases risk of graft failure and death in recent liver transplant recipients.

    Clin Gastroenterol Hepatol. 2017; 15: 584-593 e2

    • Fisher L.R.
    • Henley K.S.
    • Lucey M.R.

    Acute cellular rejection after liver transplantation: variability, morbidity, and mortality.

    Liver Transpl Surg. 1995; 1: 10-15

    • Graham J.A.
    • Torabi J.
    • Ajaimy M.
    • et al.

    Transplantation of viral-positive hepatitis C-positive kidneys into uninfected recipients offers an opportunity to increase organ access.

    Clin Transplant. 2020; 34: e13833

    • Wadei H.M.
    • Pungpapong S.
    • Cortese C.
    • et al.

    Transplantation of HCV-infected organs into uninfected recipients: advance with caution.

    Am J Transpl. 2019; 19: 960-961

    • Sawinski D.
    • Patel N.
    • Appolo B.
    • et al.

    Use of HCV+ donors does not affect HCV clearance with directly acting antiviral therapy but shortens the wait time to kidney transplantation.

    Transplantation. 2017; 101: 968-973

    • Smolders E.J.
    • Jansen A.M.E.
    • Ter Horst P.G.J.
    • et al.

    Viral hepatitis C therapy: pharmacokinetic and pharmacodynamic considerations: a 2019 update.

    Clin Pharm. 2019; 58: 1237-1263

  • Patients with renal impairment.

    () ()

  • Recommendations for testing, managing, and treating hepatitis C.

    () ()

  • EASL recommendations on treatment of hepatitis C: final update of the series(☆).

    J Hepatol. 2020; 73: 1170-1218

    • Bronster D.J.
    • Emre S.
    • Boccagni P.
    • et al.

    Central nervous system complications in liver transplant recipients–incidence, timing, and long-term follow-up.

    Clin Transplant. 2000; 14: 1-7

    • Shepard P.W.
    • St Louis E.K.

    Seizure treatment in transplant patients.

    Curr Treat Options Neurol. 2012; 14: 332-347

    • An J.
    • Shim J.H.
    • Kim S.O.
    • et al.

    Prevalence and prediction of coronary artery disease in patients with liver cirrhosis: a registry-based matched case-control study.

    Circulation. 2014; 130: 1353-1362

  • EASL recommendations on treatment of hepatitis C 2018.

    J Hepatol. 2018; 69: 461-511

    • Smolders E.J.
    • Ter Horst P.J.G.
    • Wolters S.
    • et al.

    Cardiovascular risk management and hepatitis C: combining drugs.

    Clin Pharm. 2019; 58: 565-592

    • van Seyen M.
    • Samson A.D.
    • Cullen L.
    • et al.

    Crushed application of sofosbuvir and velpatasvir in a patient with swallowing disorder.

    Int J Antimicrob Agents. 2020; 55: 105934

    • Cáceres-Velasco C.
    • Gómez-Sayago L.
    • Marín-Ventura L.
    • et al.

    5PSQ-029 Safe administration of sofosbuvir/velpatasvir in a patient with percutaneous endoscopic gastrostomy.

    British Medical Journal Publishing Group,
    2020

    • Yap J.
    • Jaiswal P.
    • Ton L.
    • et al.

    Successful treatment of chronic hepatitis C infection with crushed elbasvir/grazoprevir administered via a percutaneous endoscopic gastrostomy tube.

    J Clin Pharm Ther. 2018; 43: 730-732

  • Treatment of chronic hepatitis C virus infection with crushed ledipasvir/sofosbuvir administered via a percutaneous endoscopic gastrostomy tube.

    J Pharm Pract. 2018; 31: 522-524

    • Oberoi R.K.
    • Zhao W.
    • Sidhu D.S.
    • et al.

    A phase 1 study to evaluate the effect of crushing, cutting into half, or grinding of glecaprevir/pibrentasvir tablets on exposures in healthy subjects.

    J Pharm Sci. 2018; 107: 1724-1730

    • Bethea E.D.
    • Samur S.
    • Kanwal F.
    • et al.

    Cost effectiveness of transplanting HCV-infected livers into uninfected recipients with preemptive antiviral therapy.

    Clin Gastroenterol Hepatol. 2019; 17: 739-747. e8

    • Kadatz M.
    • Klarenbach S.
    • Gill J.
    • et al.

    Cost-effectiveness of using kidneys from hepatitis C nucleic acid test-positive donors for transplantation in hepatitis C-negative recipients.

    Am J Transplant. 2018; 18: 2457-2464

    • Goldberg D.S.
    • Abt P.L.
    • Blumberg E.A.
    • et al.

    Trial of transplantation of HCV-infected kidneys into uninfected recipients.

    N Engl J Med. 2017; 376: 2394-2395

    • Reese P.P.
    • Abt P.L.
    • Blumberg E.A.
    • et al.

    Twelve-month outcomes after transplant of hepatitis C–infected kidneys into uninfected recipients: a single-group trial.

    Ann Intern Med. 2018; 169: 273-281

    • Friebus-Kardash J.
    • Gäckler A.
    • Kribben A.
    • et al.

    Successful early sofosbuvir-based antiviral treatment after transplantation of kidneys from HCV-viremic donors into HCV-negative recipients.

    Transpl Infect Dis. 2019; 21: e13146

    • Durand C.M.
    • Bowring M.G.
    • Brown D.M.
    • et al.

    Direct-acting antiviral prophylaxis in kidney transplantation from hepatitis C virus–infected donors to noninfected recipients: an open-label nonrandomized trial.

    Ann Intern Med. 2018; 168: 533-540

    • Franco A.
    • Moreso F.
    • Merino E.
    • et al.

    Renal transplantation from seropositive hepatitis C virus donors to seronegative recipients in Spain: a prospective study.

    Transpl Int. 2019; 32: 710-716

    • Duerr M.
    • Liefeldt L.
    • Friedersdorff F.
    • et al.

    Pan-genotype pre-exposure prophylaxis (PrEP) allows transplantation of HCV-positive donor kidneys to negative transplant recipients.

    J Clin Med. 2021; 10: 89

    • Bethea E.
    • Arvind A.
    • Gustafson J.
    • et al.

    Immediate administration of antiviral therapy after transplantation of hepatitis C-infected livers into uninfected recipients: implications for therapeutic planning.

    Am J Transplant. 2020; 20: 1619-1628



  • Source link
    #Hepatitis #VirusPositive #Organs #Hepatitis #VirusNegative #Recipients

    Leave a Reply

    This site uses Akismet to reduce spam. Learn how your comment data is processed.

    %d bloggers like this: